Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it - 2The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- 3NASA funds new tech for upcoming 'Super Hubble' to search for alien life: 'We intend to move with urgency'
- 4The largest sun of 2026 rises today as Earth draws closest to our parent star
- 5Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- An Extended period of Voyaging Carefully: the World with Reason
- IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- A top Marine shares his secrets to keeping fit at 50
- Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- The Reduced Portage Horse: An Inheritance Reconsidered for Present day Experience
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- 2 ways you can conserve the water used to make your food
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
